// Real-Time Intelligence Feed

Financial Intelligence.
Real-Time.

SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.

22,616
Stories Indexed
Live
Feed Status
6
Data Sources
LATEST
AllEarningsFDAM&AInsider TradingRegulatoryOfferingLeadershipRestructuringDividendInstitutional HoldingsBankruptcy
FDA · 22,616 results Live
FDA Mallinckrodt Sep 14 — 0.00

FDA Approves TERLIVAZ — Mallinckrodt Hospital Products Inc.

Mallinckrodt Hospital Products Inc. announced FDA approval of the intravenous drug TERLIPRESSIN (Generic: TERLIPRESSIN), a significant milestone for the company’s hospital portfoli…

FDA Zydus Sep 12 — 0.00

FDA Approves LENALIDOMIDE — Zydus Pharmaceuticals USA Inc.

Zydus Pharmaceuticals USA Inc. announced on Tuesday the FDA approval of a generic version of global immunomodulatory drug manufacturer Johnson & Johnson's oral drug Lenalidomide, a…

FDA E.R. Sep 9 — 0.00

FDA Approves SOTYKTU — E.R. Squibb & Sons, L.L.C.

The FDA has granted approval to Squibb’s oral drug SOTYKTU (deucravacitinib) for the treatment of moderate-to-severe plaque psoriasis, a development that may allow the pharmaceutic…

FDA Novadoz Sep 7 — 0.00

FDA Approves VIGABATRIN — Novadoz Pharmaceuticals LLC

Novadoz Pharmaceuticals LLC has secured FDA approval for its generic Vigabatrin oral formulation, positioning the company to capitalize on cost-savings trends by entering the marke…

FDA EXELAN Sep 6 — 0.00

FDA Approves LENALIDOMIDE — EXELAN PHARMACEUTICALS INC.

# FDA Approves Generic LENALIDOMIDE; Exelan Pharmaceuticals Enters High-Value Oncology Market Exelan Pharmaceuticals Inc. received FDA approval for its generic lenalidomide oral f…

FDA MSN Sep 1 — 0.00

FDA Approves Unknown Drug — MSN

# FDA Approves ANDA for MSN The FDA has approved ANDA 211135 for MSN as of September 1, 2022, potentially expanding the company's portfolio in the generic drug market. The approva…

FDA Alvogen, Aug 31 — 0.00

FDA Approves LENALIDOMIDE — Alvogen, Inc.

# FDA Approves Generic Lenalidomide from Alvogen Alvogen, Inc. has received FDA approval for generic lenalidomide, an oral immunomodulatory drug used to treat multiple myeloma and…

FDA Mylan Aug 30 — 0.00

FDA Approves LENALIDOMIDE — Mylan Pharmaceuticals Inc.

# FDA Approves Mylan's Generic Lenalidomide Mylan Pharmaceuticals Inc. received FDA approval for generic lenalidomide, a significant immunomodulatory drug used to treat multiple m…

FDA Apotex Aug 30 — 0.00

FDA Approves LENALIDOMIDE — Apotex Corp.

Apotex Corp. received the FDA approval for its generic Lenalidomide on Aug. 30, expanding its portfolio to challenge competitors within the myeloma treatment market. The clearance …

FDA Hikma Aug 29 — 0.00

FDA Approves VIGABATRIN — Hikma Pharmaceuticals USA Inc

Hikma Pharmaceuticals USA Inc. received FDA approval for its generic oral version of Vigabatrin in August, a move expected to bolster the company's anticonvulsant portfolio and dri…

FDA Northstar Aug 29 — 0.00

FDA Approves PANTOPRAZOLE SODIUM — Northstar Rx LLC

Northstar Rx LLC has received FDA approval for IV pantoprazole sodium (ANDA 215860), a significant move that promises to bolster the availability of a first-line injectable treatme…

FDA Axsome Aug 18 — 0.00

FDA Approves AUVELITY — Axsome Therapeutics, Inc.

# FDA Approves Axsome Therapeutics' AUVELITY for Major Depressive Disorder Axsome Therapeutics received FDA approval for AUVELITY (dextromethorphan hydrobromide/bupropion hydrochl…

FDA Advagen Aug 18 — 0.00

FDA Approves ACYCLOVIR — Advagen Pharma Limited

Advagen Pharma Limited received FDA approval on August 18, 2022, for the Abbreviated New Drug Application ANDA215724, finalizing its launch of the oral acyclovir generic. This acti…

FDA AstraZeneca Aug 3 — 0.00

FDA Approves CALQUENCE — AstraZeneca Pharmaceuticals LP

# FDA Approves AstraZeneca's CALQUENCE (acalabrutinib) AstraZeneca Pharmaceuticals LP received FDA approval for CALQUENCE (acalabrutinib), an oral Bruton's tyrosine kinase inhibi…

FDA AbbVie Jun 16 — 0.00

FDA Approves SKYRIZI — AbbVie Inc.

AbbVie announced the FDA approval of risankizumab-RZAA (Skyrizi) for intravenous use, a formulation that may broaden the biologic’s market presence alongside its current subcutaneo…

FDA Camber Jun 7 — 0.00

FDA Approves NAPROXEN — Camber Pharmaceuticals, Inc.

Camber Pharmaceuticals, Inc. announced late Monday the approval of its Abbreviated New Drug Application, No. ANDA215776, for the oral formulation of Naproxen, triggering a green li…

FDA Eugia Jun 6 — 0.00

FDA Approves LEUPROLIDE ACETATE — Eugia US LLC

# FDA Approves Eugia US LLC's Generic Leuprolide Acetate Eugia US LLC received FDA approval for its generic leuprolide acetate formulation, marking another entry into the competit…

FDA Aurobindo May 10 — 0.00

FDA Approves VIGABATRIN — Aurobindo Pharma Limited

# FDA Approves Aurobindo Pharma's Generic Vigabatrin, Expanding Treatment Options for Seizure Disorders The FDA has approved Aurobindo Pharma Limited's generic formulation of viga…

FDA Teva May 4 — 0.00

FDA Approves POMALIDOMIDE — Teva Pharmaceuticals, Inc.

# FDA Approves Generic Version of Pomalidomide; Teva Gains Market Entry Teva Pharmaceuticals, Inc. received FDA approval for its generic oral pomalidomide formulation (ANDA209956)…

FDA LUPIN May 3 — 0.00

FDA Approves Unknown Drug — LUPIN LTD

# FDA Approves Lupin Ltd's Generic Drug Application Lupin Ltd has received FDA approval for generic drug application ANDA091040, expanding the company's portfolio in the competiti…